Ultime notizie per Intuitive Surgical (NASDAQ:ISRG) Azioni

Intuitive Surgical

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.

Intuitive Surgical Inc

INTUITIVE SURGICAL ORD

<p>Evercore ISI Group  analyst Vijay Kumar   maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a In-Line and raises the price target from $410 to $475.</p>


News

Price Target

Analyst Ratings

ISRG

Evercore ISI Group Maintains In-Line on Intuitive Surgical, Raises Price Target to $475

<p>Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 10 years by 13.91% on an annualized basis producing an average annual return of 25.14%. Currently, Intuitive Surgical has a market capitalization of $171.77 billion. </p>
<p><strong>Buying $100 In ISRG:</strong> If an investor had bought $100 of ISRG stock 10 years ago, it would be worth <strong>$935.83</strong> today based on a price of $483.39 for ISRG at the time of writing.</p>
<h3>Intuitive Surgical's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727276417_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

Here's How Much $100 Invested In Intuitive Surgical 10 Years Ago Would Be Worth Today

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Intuitive Surgical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ISRG, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Intuitive Surgical.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 60% bullish and 40%, bearish.</p>
<p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $63,430, and 13 are calls, for a total amount of $740,149.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $410.0 to $495.0 for Intuitive Surgical during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Intuitive Surgical stands at 164.11, with a total volume reaching 1,028.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Intuitive Surgical, situated within the strike price corridor from $410.0 to $495.0, throughout the last 30 days.</p>
<h3>Intuitive Surgical Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727123438_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$16.9</td>
<td>$16.8</td>
<td>$16.9</td>
<td>$490.00</td>
<td>$310.9K</td>
<td style="text-align: right;">309</td>
<td style="text-align: right;">256</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$84.2</td>
<td>$80.3</td>
<td>$80.82</td>
<td>$410.00</td>
<td>$80.8K</td>
<td style="text-align: right;">152</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$16.0</td>
<td>$15.9</td>
<td>$15.9</td>
<td>$492.50</td>
<td>$39.7K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">27</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$16.5</td>
<td>$16.1</td>
<td>$16.5</td>
<td>$490.00</td>
<td>$36.3K</td>
<td style="text-align: right;">309</td>
<td style="text-align: right;">302</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$40.0</td>
<td>$38.9</td>
<td>$40.0</td>
<td>$485.00</td>
<td>$36.0K</td>
<td style="text-align: right;">169</td>
<td style="text-align: right;">82</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intuitive Surgical</h3>
<p>Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.</p>
<p>Following our analysis of the options activities associated with Intuitive Surgical, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Intuitive Surgical</h3>
<ul>
<li>With a volume of 868,586, the price of ISRG is up 0.59% at $489.07. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 24 days.</li>
</ul>
<h3>What The Experts Say On Intuitive Surgical</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $494.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from BTIG keeps a Buy rating on Intuitive Surgical with a target price of $494. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Intuitive Surgical, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

Intuitive Surgical Unusual Options Activity For September 23

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Intuitive Surgical</strong>.</p>
<p>Looking at options history for Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) we detected 10 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 10% of the investors opened trades with bullish expectations and 60% with bearish.</p>
<p>From the overall spotted trades, 2 are puts, for a total amount of $154,180 and 8, calls, for a total amount of $348,579.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $455.0 to $480.0 for Intuitive Surgical over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Intuitive Surgical's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Intuitive Surgical's whale activity within a strike price range from $455.0 to $480.0 in the last 30 days. </p>
<h3>Intuitive Surgical 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726669873_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$20.2</td>
<td>$18.7</td>
<td>$19.5</td>
<td>$455.00</td>
<td>$128.7K</td>
<td style="text-align: right;">160</td>
<td style="text-align: right;">104</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$21.0</td>
<td>$20.1</td>
<td>$20.11</td>
<td>$480.00</td>
<td>$98.5K</td>
<td style="text-align: right;">266</td>
<td style="text-align: right;">203</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$21.2</td>
<td>$20.2</td>
<td>$20.3</td>
<td>$480.00</td>
<td>$58.8K</td>
<td style="text-align: right;">266</td>
<td style="text-align: right;">71</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$21.3</td>
<td>$20.3</td>
<td>$20.3</td>
<td>$480.00</td>
<td>$42.6K</td>
<td style="text-align: right;">266</td>
<td style="text-align: right;">70</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$21.4</td>
<td>$20.2</td>
<td>$20.4</td>
<td>$480.00</td>
<td>$32.6K</td>
<td style="text-align: right;">266</td>
<td style="text-align: right;">49</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intuitive Surgical</h3>
<p>Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.</p>
<p>After a thorough review of the options trading surrounding Intuitive Surgical, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Intuitive Surgical Standing Right Now?</h3>
<ul>
<li>With a trading volume of 132,527, the price of ISRG is down by -0.52%, reaching $480.82.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 29 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Intuitive Surgical</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $527.0.</p>
<ul>
<li>Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Intuitive Surgical, targeting a price of $560. </li>
<li>Consistent in their evaluation, an analyst from BTIG keeps a Buy rating on Intuitive Surgical with a target price of $494. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Intuitive Surgical, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Intuitive Surgical's Options: A Look at What the Big Money is Thinking

<p><strong>OrthoPediatrics Corp.&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kids#NASDAQ">KIDS</a>) recently launched its Enabling Technologies division, which will leverage the company&#39;s core mission of addressing unmet pediatric needs in orthopedics.</p>
<p>The advancement with the latest launch positions OrthoPediatrics at the forefront of the pediatric digital health and enabling technologies sectors.</p>
<p>Following the announcement, shares of OrthoPediatrics rose 2.15% to $32.38 on Friday. The company continues to gain a high level of synergies from its various latest developments within the pediatric digital health space. Accordingly, we expect market sentiment to continue to remain positive around this announcement.</p>
<h2>More on OrthoPediatrics&#39; Enabling Technologies Division</h2>
<p>Led by industry veteran Kevin Unger, this new division is set to differentiate OrthoPediatrics&#39; core business, generate sustainable revenue growth, and gain access to new markets and specialties beyond orthopedics.</p>
<p>The company has made significant strides in the field through its distribution of the 7D Flash Navigation System. Additionally, it collaborated with 3D Side, S.A. for patient-specific cutting guides. These innovations have laid a strong foundation for the Enabling Technologies division.</p>
<h2>OrthoPediatrics&#39; Business Advancements</h2>
<p>Given the success of the above-mentioned developments, KIDS is all set to launch its two groundbreaking technology platforms. First, Playbook is a cutting-edge surgical workflow and outcome optimization platform. It is designed to enhance surgical planning, collaboration and intraoperative workflow. Playbook is aimed at revolutionizing how surgeries are planned and executed, potentially resulting in improved outcomes and more efficient processes.</p>
<p>Second, Robotic-Assistance is for Cochlear Implant Technology.OrthoPediatrics partnered with iotaMotion, Inc. to bring a robotic-assisted insertion system to enhance cochlear implant surgery. This technology offers a slow electrode array insertion that is agnostic to cochlear implant manufacturers, providing greater control and precision for pediatric patients.</p>
<h2>Other Recent Developments by OrthoPediatrics</h2>
<p>In May, the company received the &quot;Breakthrough Device&quot; designation from the&nbsp;Food and Drug Administration&nbsp;for its new eLLi surgical device. eLLi is an implant designed to address severe pathology associated with early onset scoliosis, which can be associated with thoracic insufficiency, a potentially life-threatening condition. This innovative product should be a great addition to the suite of products for pediatric patients with scoliosis.</p>
<p>Earlier this year, OrthoPediatrics launched a new RESPONSE Rib and Pelvic Fixation system to treat children with EOS. The system represents&nbsp;OrthoPediatrics&#39;&nbsp;first solution to treat patients at risk of thoracic insufficiency syndrome. The new addition to the RESPONSE portfolio includes implants and instruments for rib and pelvic fixation, and associated devices to connect the fixation points.&nbsp;</p>
<h2>Industry Prospects Favor OrthoPediatrics</h2>
<p>Per a Grand View Research report, the global pediatric orthopedic devices market was valued at $3.83 billion in 2023 and is projected to witness a CAGR of 11.0% from 2024 to 2030.</p>
<p>Primary factors behind the projected market surge include growing awareness of orthopedic conditions in children and the rise in congenital &amp; developmental disorders. Furthermore, innovations such as adjustable &amp; customizable devices and improved materials for better functionality &amp; safety are fueling market growth.</p>
<p>Henceforth, OrthoPediatrics&#39; latest announcement is well-timed.</p>
<h2>KIDS&#39; Price Performance</h2>
<p>Year to date, shares of KIDS have risen 0.7% compared with the industry&#39;s 9.3% growth.</p>
<h2>KIDS&#39; Zacks Rank and Other Key Picks</h2>
<p>KIDS currently carries a Zacks Rank #2 (Buy).</p>
<p>Some other top-ranked stocks in the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), <strong>TransMedics Group </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and <strong>Boston Scientific&nbsp;</strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>). While Intuitive Surgical and TransMedics currently sport a Zacks Rank #1 (Strong Buy) each, Boston Scientificcarries a Zacks Rank #2.</p>
<p>Intuitive Surgical&#39;s shares have surged 64.3% in the past year. Estimates for the company&#39;s earnings have moved north 5.1% to $1.65 per share for 2024 in the past 30 days.</p>
<p>ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.</p>
<p>Estimates for TransMedics&#39; 2024 EPS have moved up 125% to 27 cents in the past 30 days. Shares of the company have soared 156.9% in the past year compared with the industry&#39;s 17.5% growth.</p>
<p>TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 57.2% compared with the industry&#39;s 19.5% growth.</p>
<p>In the last reported quarter, BSX delivered an earnings surprise of 6.90%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.</p>
<p><a href="https://www.zacks.com/stock/news/2336322/kids-stock-gains-from-its-new-enabling-technologies-division-launch?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2336322">To read this article on Zacks.com click here.</a></p>


Biotech

Earnings

Earnings Beats

Large Cap

Mid Cap

Small Cap

General

KIDS

TMDX

KIDS Stock Gains From Its New Enabling Technologies Division Launch

<p><strong>Sanara MedTech Inc.&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smti#NASDAQ">SMTI</a>), along with InfuSystem Inc., recently entered into an exclusive U.S. distribution agreement with ChemoMouthpiece, LLC. Sanara will execute the terms of the agreement with the help of SI Healthcare Technologies (SI Technologies), which is a 50/50 joint venture between SMTI and InfuSystem.</p>
<p>ChemoMouthpiece owns and manufactures a clinically validated product named Chemo Mouthpiece &mdash; an oral cryotherapy device that brings relief to oral mucositis-affected patients. This device perfectly aligns with Sanara&#39;s skincare strategy. The company further aims to provide the device to oncology patients undergoing chemotherapy.</p>
<p>Following the announcement, shares of Sanara rose 0.5% to $33.51 yesterday. With the company gaining a high level of synergies from its collaborations within the skincare market, we expect market sentiment to remain positive around this development.</p>
<h2>About Sanara&#39;s Distribution Agreement With ChemoMouthpiece</h2>
<p>Under the agreement, SI Technologies will be the exclusive distributor of ChemoMouthpiece&#39;s kits in the United States. SI Technologies plans to market and distribute the product to approximately 3,000 cancer centers through InfuSystem&#39;s existing sales team. It will purchase&nbsp;the product kits from ChemoMouthpiece at a fixed price and pay a royalty on net revenues for the use of the product&#39;s intellectual property.</p>
<p>For investors&#39; note, the Chemo Mouthpiece is FDA 501(k) approved.</p>
<h2>Financial Details</h2>
<p>Sanara invested $5 million for a 6.6% ownership in ChemoMouthpiece. Sanara has drawn $15.5 million on its term loan with CRG Servicing, LLC and will fund this investment as part of that draw.</p>
<p>SI Technologies will have the option to purchase the U.S. business of ChemoMouthpiece, including all U.S. intellectual property related to the product. The purchase option will expire on Jan. 31, 2029.</p>
<h2>More on the News</h2>
<p>Oral mucositis causes painful mouth ulcers, which are a common complication of chemotherapy and radiation. The oral cryotherapy device is expected to reduce material costs for oncology treatment centers, improve patient quality of life and allow for continued treatment of cancer therapy for patients. ChemoMouthpiece is planning to publish studies in the future to reinforce the efficacy of the device.</p>
<p>Pickwick Capital Partners, LLC, served as the exclusive advisor to ChemoMouthpiece on this transaction.</p>
<h2>Recent Development by Sanara</h2>
<p>Earlier this year, Sanara signed an exclusive license agreement with Tufts University (Tufts) to develop and commercialize patented technology covering 18 unique collagen peptides.&nbsp;</p>
<p>Although Sanara has established itself as a leader in bioactive collagen peptides with CellerateRX&nbsp;Surgical Powder, the company expects to expand the CellerateRX product line and develop new bioactive collagen peptide-based applications. The recently licensed technology from Tufts helped the company to expand its offering of collagen products.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/aa/77485.jpg?v=996577913" /></p>
<p>Image Source: Zacks Investment Research</p>
<h2>Industry Prospects Favor Sanara</h2>
<p>Per a Global Market Insights report, the oral mucositis treatment market was valued at $1.6 billion in 2023 and is expected to witness a CAGR of 7.1% from 2024 to 2032.&nbsp;</p>
<p>Market growth can be attributed to the ongoing advancements in cancer therapy and the increasing prevalence of cancer. Moreover, the rising geriatric population, along with the growing demand for targeted therapies, helps the market surge.</p>
<h2>Price Performance by Sanara</h2>
<p>In the past year, shares of SMTI have lost 5.8% against the industry&#39;s 18.4% growth.</p>
<h2>SMTI&#39;s Zacks Rank and Key Picks</h2>
<p>Sanara currently carries a Zacks Rank #4 (Sell).</p>
<p>Some better-ranked stocks in the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), <strong>TransMedics Group </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and Boston Scientific. While Intuitive Surgical and TransMedics currently sport a Zacks Rank #1 (Strong Buy) each, Boston Scientificcarries a Zacks Rank #2 (Buy).</p>
<p>Intuitive Surgical&#39;s shares have surged 62.2% in the past year. Estimates for the company&#39;s earnings have moved north 5.1% to $1.65 per share for 2024 in the past 30 days.</p>
<p>ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.</p>
<p>Estimates for TransMedics&#39; 2024 EPS have moved up 125% to 27 cents in the past 30 days. Shares of the company have soared 143.8% in the past year compared with the industry&#39;s 15.8% growth.</p>
<p>TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 55.9% compared with the industry&#39;s 18.3% growth.</p>
<p>In the last reported quarter, BSX delivered an earnings surprise of 6.90%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.</p>
<p><a href="https://www.zacks.com/stock/news/2335233/sanara-stock-gains-from-new-us-distribution-deal-with-chemomouthpiece?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2335233">To read this article on Zacks.com click here.</a></p>


Health Care

SMTI

Sanara Stock Gains From New US Distribution Deal With ChemoMouthPiece

<p><strong>ResMed Inc.</strong>&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rmd#NYSE">RMD</a>) growth is backed by its impressive global Mask sales growth. Of late, the company has been experiencing increased Device sales, reflecting the ongoing combined availability of AirSense 10 and AirSense 11 sleep devices.&nbsp;However, concerns loom over ResMed&#39;s escalating debt level and the adverse impact of macroeconomic challenges.</p>
<p>In the past year, this Zacks Rank #3 (Hold) company&#39;s shares have surged 66.9% compared with 16.9% growth of the&nbsp;industry.&nbsp;The S&amp;P 500 composite rose 21.1% during the same time frame.</p>
<p>The renowned medical device company has a market capitalization of $37.15 billion. ResMed projects an estimated earnings growth rate of 15.4% for 2025 compared with 15.3% of the industry. In the trailing four quarters, RMD delivered an average earnings surprise of 4.47%.</p>
<p>Let&#39;s delve deeper.</p>
<h2>ResMed: Key Upsides</h2>
<p><strong>Robust Mask Sales</strong>: ResMed continues to see strong demand for its market-leading mask portfolio. Continued product development is driving growth within this business globally. The company has successfully introduced a full suite of masks in its AirFit and, AirTouch and other ranges. It continues to witness strong growth in the U.S. Mask and accessories business, where resupply programs are powered by its digital health ecosystem, including AirView for physicians, Brightree for home care medical equipment providers and myAir for patients. RMD&#39;s recently introduced AirFit F40 performed extremely well in the United States during the fiscal fourth quarter.</p>
<p><strong>Recovery in Device Sales</strong>: ResMed&#39;s increased Device sales continue to drive overall revenue growth, reflecting the ongoing combined availability of AirSense 10 and AirSense 11 sleep devices to support the strong underlying global demand. The company has consistently witnessed strong sales within this business with the launch of its new platform of connected CPAP and APAP devices, AirSense 11.</p>
<p>Total devices accounted for approximately 52% of net revenues in fiscal 2024. Global Device sales grew 8% reportedly and 7% on a constant currency basis in the financial year. Sales of flow generator devices, including the AirSense 11 platform, grew 6% year over year globally.</p>
<h2>ResMed: Key Downsides</h2>
<p><strong>Escalating Debt Level</strong>: The company&#39;s high debt level is a concern. As of June 31, 2024, long-term debt was $697.3 million, while cash and cash equivalents totaled $238.4 million. A higher debt level induces higher interest payments, thereby increasing the risk of failure to repay debt. At the end of the fourth quarter of fiscal 2024, the company had a payout rate of 24.8%, down sequentially.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/5d/77285.jpg?v=1887241780" /></p>
<p>Image Source: Zacks Investment Research</p>
<p><strong>Challenging Macroeconomic Scenario</strong>: Global macroeconomic conditions, primarily headwinds arising from the Middle East conflict, are denting growth. Further, fluctuations in foreign currency exchange rates and volatility in capital markets could continue to affect ResMed&#39;s results of operations.&nbsp;Due to unfavorable general economic conditions, ResMed&#39;s profitability could decline and negatively impact its overall financial performance. During the fiscal fourth quarter, SG&amp;A and R&amp;D expenses rose 0.6% and 3.5%, respectively, year over year.</p>
<h2>Estimate Trend</h2>
<p>The Zacks Consensus Estimate for 2025 earnings per share has moved north 2.2% to $8.91 in the past 30 days.</p>
<p>The Zacks Consensus Estimate for the company&#39;s 2025 revenues is pegged at $5.03 billion, suggesting a 7.3% rise from the year-ago reported number.</p>
<h2>Key Picks</h2>
<p>Some better-ranked stocks in the broader medical space are&nbsp;<strong>TransMedix Group</strong>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>),&nbsp;<strong>Intuitive Surgical </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>) and Boston Scientific.</p>
<p>TransMedix Group&#39;s earnings are expected to surge 255.8% in 2024. The company&#39;s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%. Shares of the company have risen 127.9% in the past year compared with the industry&#39;s 13.9% growth.</p>
<p>TMDX sports a Zacks Rank #1 (Strong Buy) at present.</p>
<p>Intuitive Surgical, sporting a Zacks Rank of 1 at present, has an estimated long-term earnings growth rate of 17.4% compared with the industry&#39;s 13.7%. Shares of the company have risen 60.1% compared with the industry&#39;s 13.9% growth over the past year.</p>
<p>ISRG&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.97%.</p>
<p>Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated earnings growth rate of 17.1% for 2024 compared with the industry&#39;s 15.7%. In the past year, shares of BSX have risen 52.9% compared with the industry&#39;s 16.9% growth.</p>
<p>BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.</p>
<p><a href="https://www.zacks.com/stock/news/2334520/reasons-to-retain-resmed-stock-in-your-portfolio-for-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2334520">To read this article on Zacks.com click here.</a></p>


Reasons to Retain ResMed Stock in Your Portfolio for Now

<p><strong>Intuitive Surgical's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NYSE">ISRG</a>) short percent of float has risen 10.42% since its last report. The company recently reported that it has <strong>3.74 million shares sold short</strong>, which is 1.06% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.48 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Intuitive Surgical Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726060521_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Intuitive Surgical has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Intuitive Surgical's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Intuitive Surgical's peer group average for short interest as a percentage of float is 2.85%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

How Is The Market Feeling About Intuitive Surgical?

<p><strong>Trinity Biotech plc&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trib#NASDAQ">TRIB</a>) recently provided an update on its continued development of its glucose biosensor technology. Earlier this year, the company was granted a European patent for a novel method that enhances the performance of its glucose biosensor. Recent testing of this patented process has confirmed its effectiveness in improving the performance of the sensor.</p>
<p>Trinity Biotech intends to use this breakthrough process to stabilize and improve the functionality of its glucose biosensor in its next-generation continuous glucose monitor (CGM) technology.</p>
<p>Shares of TRIB went down marginally by 0.05% in pre-market trading today following the news. However, as the company is gaining a high level of synergies from its continued development within the CGM market, this latest development might prove fruitful in strengthening its foothold in this space. Accordingly, we expect market sentiment to recover shortly.</p>
<h2>Significance of Trinity Biotech&#39;s Patented Process</h2>
<p>CGMs are small patch-like wearable medical devices that use biosensor wires under the skin to measure glucose in real time. Generally, these devices experience a &quot;run-in&quot; or &quot;settling&quot; period immediately after their insertion. During the run-in period, glucose readings are unreliable.&nbsp;</p>
<p>Trinity Biotech&#39;s patent describes a unique process within the company&#39;s reusable transmitter unit that &quot;conditions&quot; the CGM biosensor wire. This conditioning process significantly reduces this run-in time, enabling reliable measurements more quickly.&nbsp;</p>
<p>Additionally, the conditioning process has demonstrated notable improvements in the accuracy of the CGM device compared to laboratory reference methods for blood glucose testing. The process also improves the biosensor&#39;s mean absolute relative difference, which is the standard measure of accuracy used to compare CGM devices.</p>
<h2>More on the News</h2>
<p>The technology covered by this patent represents a major advancement for the company&#39;s CGM platform. The CGM technology, which Trinity Biotech acquired in January, has a unique self-inserted biosensor wire. It poses strong advantages in terms of affordability and sustainability.</p>
<p>The patented conditioning process will likely play an important role in further enhancing the CGM technology toward a more user-friendly and self-calibrating device.&nbsp;Along with other refinements to the biosensor, its wire design will be further evaluated in the upcoming pre-pivotal trials to create an optimized CGM that can be rapidly introduced into global markets.</p>
<h2>Industry Prospects Favor Trinity Biotech</h2>
<p>Per a Coherent Market Insights report, the global CGM device market was valued at $5.89 billion in 2022 and is expected to reach $12.51 billion by 2030, at a CAGR of 9.9% during the period.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/d3/77157.jpg?v=1373072611" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>The market&#39;s growth is fueled by rising diabetes awareness and the increasing prevalence of diabetes among the population. The worrisome rise in the number of overweight and obese people around the world is expected to boost demand for CGM devices.&nbsp;</p>
<h2>Recent Development by Trinity Biotech</h2>
<p>In May, Trinity Biotech made a strategic collaboration with PulseAI to enhance the former&#39;s recently acquired CGM biosensor technology. Under the collaboration, PulseAI has access to Trinity Biotech&#39;s unique multi-parameter CGM database. Further, the data is used to design and implement Trinity Biotech&#39;s AI-driven health &amp; wellness analytics platform. This platform is a key component in Trinity Biotech&#39;s CGM solution.&nbsp;</p>
<h2>Price Performance of Trinity Biotech</h2>
<p>Year to date, shares of TRIB have lost 17.4% against the industry&#39;s 8.5% growth.</p>
<h2>TRIB&#39;s Zacks Rank and Other Key Picks</h2>
<p>TRIB currently carries a Zacks Rank #2 (Buy).</p>
<p>Some other top-ranked stocks in the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), <strong>TransMedics Group </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and <strong>Boston Scientific </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>). While Intuitive Surgical and TransMedics sport a Zacks Rank #1 (Strong Buy) each, Boston Scientific currently carries a Zacks Rank #2.</p>
<p>Intuitive Surgical&#39;s shares have surged 58.6% in the past year. Estimates for the company&#39;s earnings have remained constant at $6.67 per share for 2024 in the past 30 days.</p>
<p>ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.</p>
<p>Estimates for TransMedics&#39; 2024 earnings per share have moved up 48.1% to $1.20 in the past 30 days. Shares of the company have risen 134% in the past year compared with the industry&#39;s 12.8% growth.</p>
<p>TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 51.5% compared with the industry&#39;s 15.5% growth.</p>
<p>In the last reported quarter, BSX delivered an earnings surprise of 6.90%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.</p>
<p><a href="https://www.zacks.com/stock/news/2334051/will-trinity-biotech-stock-gain-from-its-latest-patent-process?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2334051">To read this article on Zacks.com click here.</a></p>


Penny Stocks

TRIB

Will Trinity Biotech Stock Gain From Its Latest Patent Process?

<p>High-rolling investors have positioned themselves bearish on Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ISRG often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 12 options trades for Intuitive Surgical. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 16% bullish and 66% bearish. Among all the options we identified, there was one put, amounting to $108,150, and 11 calls, totaling $377,465.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $410.0 and $460.0 for Intuitive Surgical, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Intuitive Surgical's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Intuitive Surgical's substantial trades, within a strike price spectrum from $410.0 to $460.0 over the preceding 30 days.</p>
<h3>Intuitive Surgical Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725634917_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/13/24</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$460.00</td>
<td>$108.1K</td>
<td style="text-align: right;">28</td>
<td style="text-align: right;">6</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$96.3</td>
<td>$95.7</td>
<td>$95.7</td>
<td>$410.00</td>
<td>$47.8K</td>
<td style="text-align: right;">34</td>
<td style="text-align: right;">8</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$96.3</td>
<td>$94.2</td>
<td>$95.15</td>
<td>$410.00</td>
<td>$47.5K</td>
<td style="text-align: right;">34</td>
<td style="text-align: right;">8</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$88.7</td>
<td>$86.2</td>
<td>$88.7</td>
<td>$420.00</td>
<td>$44.3K</td>
<td style="text-align: right;">175</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$88.7</td>
<td>$85.8</td>
<td>$88.26</td>
<td>$420.00</td>
<td>$44.1K</td>
<td style="text-align: right;">175</td>
<td style="text-align: right;">5</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intuitive Surgical</h3>
<p>Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.</p>
<p>After a thorough review of the options trading surrounding Intuitive Surgical, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Intuitive Surgical's Current Market Status</h3>
<ul>
<li>Trading volume stands at 263,434, with ISRG's price down by -1.66%, positioned at $468.76.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 41 days.</li>
</ul>
<h3>What Analysts Are Saying About Intuitive Surgical</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $527.0.</p>
<ul>
<li>Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Intuitive Surgical with a target price of $560. </li>
<li>Consistent in their evaluation, an analyst from BTIG keeps a Buy rating on Intuitive Surgical with a target price of $494. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Intuitive Surgical, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Decoding Intuitive Surgical's Options Activity: What's the Big Picture?

<p>Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 15 years by 9.49% on an annualized basis producing an average annual return of 21.17%. Currently, Intuitive Surgical has a market capitalization of $170.67 billion. </p>
<p><strong>Buying $100 In ISRG:</strong> If an investor had bought $100 of ISRG stock 15 years ago, it would be worth <strong>$1,743.35</strong> today based on a price of $480.27 for ISRG at the time of writing.</p>
<h3>Intuitive Surgical's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725564620_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $100 Invested In Intuitive Surgical 15 Years Ago Would Be Worth Today

<p><strong>Phibro Animal Health&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>) delivered adjusted earnings per share of 41 cents in the fourth quarter of fiscal 2024, up 7.9% from the year-ago quarter&#39;s level. The bottom line beat the Zacks Consensus Estimate by 20.6%.</p>
<p>Without adjustments, the GAAP EPS in the quarter was 2 cents, down 92.9% from the year-ago quarter&#39;s figure.</p>
<p>PAHC reported full-year adjusted EPS of $1.19, reflecting a 1.7% decline from fiscal 2023. The figure beat the Zacks Consensus Estimate by 6.25%.</p>
<h2>PAHC&#39;s Net Sales</h2>
<p>In the quarter under review, net sales totaled $273.2 million, up 7.1% from the year-ago quarter&#39;s level. The figure also topped the Zacks Consensus Estimate by 4.1%.</p>
<p>For fiscal 2024, the company reported net sales of $1.02 billion, up 4.1% from the prior-year level. The figure beat the Zacks Consensus Estimate by a marginal 1%.</p>
<h2>Phibro&#39;s Segmental Sales</h2>
<p>The company conducts its operations via three segments &mdash; Animal Health, Mineral Nutrition and Performance Products.</p>
<p>In the fourth quarter of fiscal 2024,&nbsp;<strong>Animal Health</strong>&#39;s net sales increased 8% to $191.5 million. Within the segment, net sales of medicated feed additives (MFAs) and others reflected 12% year-over-year growth. The uptick was driven by the increased demand for MFAs in both domestic and international regions and higher demand for processing aids used in the ethanol fermentation industry. The top line surpassed our model&#39;s projection of $181.8 million by 5.3%.</p>
<p>Nutritional specialty product sales decreased 4%, primarily due to lower demand for dairy products. However, net vaccine sales showed a year-over-year rise of 14%, mostly due to poultry product introductions in Latin America, along with an increase in domestic and international demand.</p>
<p>Net sales in the&nbsp;<strong>Mineral Nutrition</strong>&nbsp;segment rose 6% year over year to $62.1 million due to increased sales volume and higher average selling price. The top line surpassed our model&#39;s projection of $61.9 million by a marginal 0.3%.</p>
<p>Net sales in the&nbsp;<strong>Performance Products</strong>&nbsp;segment fell 1% to $19.6 million as a result of the decreased demand for personal care product ingredients and industrial chemicals. The top line surpassed our model&#39;s projection of $18 million by 8.9%.</p>
<h2>Phibro Animal Health Corporation Price, Consensus and EPS Surprise</h2>
<div class="chart_embed"><img alt="Phibro Animal Health Corporation Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/9c/1724935133.png" style="height:265px; width:577px" title="" /></div>
<div class="chart_embed">Phibro Animal Health Corporation price-consensus-eps-surprise-chart | Phibro Animal Health Corporation Quote</div>
<h2>PAHC&#39;s Margin Performance</h2>
<p>Phibro&#39;s fiscal fourth-quarter gross profit rose 13.8% year over year to $87.2 million. The gross margin expanded 188 basis points (bps) to 31.9% despite a 4.3% rise in the cost of goods sold.</p>
<p>SG&amp;A expenses in the reported quarter were $68.7 million, up 29.9% from the year-ago quarter&#39;s levels. The operating profit declined 21% year over year to $18.5 million and the operating margin contracted 252 bps to 6.8% in the quarter under review.</p>
<h2>PAHC&#39;s Financial Update</h2>
<p>The company exited the fourth quarter of fiscal 2024 with cash and short-term investments of $114.6 million compared with $98.7 million at the end of the fiscal third quarter.</p>
<p>Cumulative net cash provided by operating activities at the end of fiscal 2024 was $87.6 million compared with $13.3 million in the year-ago period.</p>
<h2>Phibro&#39;s Fiscal 2025 Guidance</h2>
<p>The company expects net sales to be between $1.04 billion and $1.09 billion. The Zacks Consensus Estimate for the metric is pegged at $1.25 billion.</p>
<p>Adjusted EPS is expected to be in the range of $1.22-$1.37. The Zacks Consensus Estimate for the same is pegged at $1.43.</p>
<h2>Our Take on Phibro&#39;s Q4 Results</h2>
<p>Phibro delivered better-than-expected revenues and earnings in the reported quarter. The core Animal Health segment benefited from the robust performance of the vaccine, MFAs and other businesses. Additionally, the Mineral Nutrition Products segment reported year-over-year growth.</p>
<p>The anticipated closing of the Zoetis Medicated Feed Additive portfolio acquisition in the coming months may lead to strong earnings accretion. It can also drive investments in the faster-growing vaccines, nutritional specialties and companion animal product segments.</p>
<p>Meanwhile, the contraction of the operating margin in the quarter is discouraging. Declining revenues from the Performance Products segment raise concern.</p>
<h2>PAHC&#39;s Zacks Rank &amp; Other Key Picks</h2>
<p>Phibro currently carries a Zacks Rank #2 (Buy).</p>
<p>Some other top-ranked stocks from the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), TransMedics Group&nbsp;and <strong>Quest Diagnostics</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>).</p>
<p>Intuitive Surgical reported a second-quarter 2024 adjusted EPS of $1.78, which beat the Zacks Consensus Estimate by 16.3%. Revenues of $2.01 billion topped the consensus estimate by 2%. ISRG currently sports a Zacks Rank #1 (Strong Buy).</p>
<p>Intuitive Surgical has a long-term five-year earnings growth rate of 17.4% compared with the industry&#39;s 13.7%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.97%.</p>
<p>TransMedics, carrying a Zacks Rank #1 at present, reported second-quarter 2024 earnings of 35 cents per share, which surpassed the Zacks Consensus Estimate by 66.7%. Revenues of $114.3 million topped the Zacks Consensus Estimate by 15.9%.</p>
<p>TMDX has an earnings growth rate of 51.7% for 2025 compared with the S&amp;P 500&#39;s 11.3%. The company beat on earnings in each of the trailing four quarters, the average surprise being 287.50%.</p>
<p>Quest Diagnostics, carrying a Zacks Rank #2 (Buy) at present, reported a second-quarter adjusted EPS of $2.35, which surpassed the Zacks Consensus Estimate by 1.7%. Revenues of $2.40 billion outpaced the Zacks Consensus Estimate by 0.5%.</p>
<p>DGX has a historical five-year earnings growth rate of 7.4% compared with the industry&#39;s 4.2%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.31%.</p>
<p><a href="https://www.zacks.com/stock/news/2328933/phibro-q4-earnings-and-revenues-beat-operating-margin-down?cid=CS-BENZ-FT-analyst_blog|earnings_article-2328933">To read this article on Zacks.com click here.</a></p>


Guidance

PAHC

Phibro Q4 Earnings and Revenues Beat, Operating Margin Down

<p><strong>Neogen</strong>&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/neog#NASDAQ">NEOG</a>) vast international trade is impacted by global macroeconomic issues. Also, a tough competitive landscape weighs on the stock. NEOG stock carries a Zacks Rank #4 (Sell).</p>
<p>Neogen&#39;s international business continues to be affected by currency movements.</p>
<p>The current macroeconomic environment has adversely impacted Neogen&#39;s financial operations. Governments and insurance companies continue to look for ways to contain the rising cost of healthcare. This might put pressure on players in the healthcare industry, with Neogen being no exception.&nbsp; Although the company is gradually coming out of the impact of the two-and-a-half-year-long pandemic, deteriorating international trade, with global inflationary pressure leading to a tough situation related to raw material and labor cost as well as freight charges, and a higher interest rate have put the medical device space in a tight spot.</p>
<p>With sustained macroeconomic pressure, the company may struggle to keep its cost of revenues and operating expenses in check. In fiscal 2024, sales and marketing expenses rose 29.5% year over year. Our model forecasts a 1.5% rise in the metric for fiscal 2025.</p>
<p>Further, Neogen faces intense competition from companies ranging from small businesses to divisions of large multinational companies. Some of these organizations have substantially greater financial resources than the company. Historically, Neogen has faced intense competition resulting from the development of new technologies by the company&#39;s competitors, which could affect the marketability and profitability of Neogen&#39;s products.</p>
<h2>Factors That May Offset the Risks for NEOG Stock</h2>
<p>Neogen is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets. In the fiscal fourth quarter, the Indicator Testing, Culture Media &amp; Other product categories benefited from double-digit growth in the Petrifilm product line as well as solid growth in culture media and food quality nutritional analysis. Additionally, the Vet Instruments and Disposables product line witnessed solid core growth. In the Animal care and other product category, core growth was led by higher sales of vitamin injectables and Biologics products.</p>
<div class="chart_embed">
<h2>Neogen Corporation Price</h2>
<p><img alt="Neogen Corporation Price" src="https://staticx-tuner.zacks.com/images/charts/a6/1724841357.png" style="height:251px; width:538px" title="" /></p>
<p>Neogen Corporation price | Neogen Corporation Quote</p>
<p>Neogen also continues to carry out its strong R&amp;D activities. During the fiscal fourth quarter, Neogen&#39;s R&amp;D expenses totaled $5.1 million, up sequentially 4.1%.</p>
</div>
<p>The company is expanding well in other geographies. The company is seeing double-digit sales growth in Latin America, with strong performance across most key product categories.&nbsp; The business in Europe and Asia Pacific grew in low single digits and mid-single digits, respectively, with strength in Culture media, Petrifilm, General Sanitation and Sample Handling.</p>
<h2>Key Picks</h2>
<p>Some better-ranked stocks in the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), <strong>TransMedics Group </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and <strong>Boston Scientific </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>). While Intuitive Surgical and TransMedics sport a Zacks Rank #1 (Strong Buy) each, Boston Scientific currently carries a Zacks Rank of 2 (Buy).</p>
<p>Intuitive Surgical&#39;s shares have surged 55.4% in the past year. Estimates for the company&#39;s earnings have remained constant at $6.67 per share for 2024 in the past 30 days.</p>
<p>ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.</p>
<p>Estimates for TransMedics&#39; 2024 earnings per share have moved up 48.1% to $1.20 in the past 30 days. Shares of the company have risen 174.1% in the past year compared with the industry&#39;s 9.2% growth.</p>
<p>TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 46% compared with the industry&#39;s 9.2% growth.</p>
<p>In the last reported quarter, BSX delivered an earnings surprise of 6.90%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.</p>
<p><a href="https://www.zacks.com/stock/news/2328483/neogen-suffers-from-competitive-pressure-macroeconomic-woes?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2328483">To read this article on Zacks.com click here.</a></p>


Macro Economic Events

Economics

NEOG

Neogen Suffers From Competitive Pressure, Macroeconomic Woes

<p>BTIG  analyst Ryan Zimmerman   maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Buy and raises the price target from $469 to $494.</p>


BTIG Maintains Buy on Intuitive Surgical, Raises Price Target to $494

<p><strong>ICON plc&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iclr#NASDAQ">ICLR</a>) is well-poised to grow in the coming quarters, driven by its meaningful strategic additions. The company is committed to improving patient access and engagement strategy. Meanwhile, concerns about the adverse macroeconomic impacts as well as currency fluctuations remain, which may hamper ICON&#39;s performance.</p>
<p>In the past year, this Zacks Rank #3 (Hold) company has gained 27% compared with the&nbsp;industry&#39;s 9.9% growth and 27.1% rise of the S&amp;P 500 composite.</p>
<p>The leading healthcare intelligence and clinical research organization has a market capitalization of $26.85 billion. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 0.92%.</p>
<p>Let&#39;s delve deeper.</p>
<h2>Tailwinds</h2>
<p><strong>Focus on Patient Access &amp; Engagement Strategy: </strong>ICON is continuously improving in site identification, study placement and patient recruitment and retention through its focused patient, site and data strategy.</p>
<p>In line with this, Accellacare, ICON&#39;s global clinical research network, is offering customers a wide range of stand-alone and integrated solutions at the site or in patients&#39; homes as part of decentralized trials. One of the key strategic moves of ICON in 2024 was a focused rebranding of its specialized biotech solutions division, ICON Biotech.</p>
<p>During the second quarter of 2024, the company experienced positive constructive progress in the biotech funding area.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/34/75344.jpg?v=190607711" /></p>
<p>Image Source: Zacks Investment Research</p>
<p><strong>Strategic Pacts to Drive Growth:&nbsp;</strong>ICON is focused on expanding its business through strategic acquisitions and partnerships. The company&#39;s acquisition of HumanFirst in January 2024 is strategically aligned with its approach to provide an enhanced integrated offering.</p>
<p>ICON also partnered with the U.S. Biomedical Advanced Research and Development Authority to execute a clinical trial to evaluate the effectiveness of the next-generation COVID vaccine candidates.</p>
<h2>Headwinds</h2>
<p><strong>Macroeconomic Pressure:&nbsp;</strong>Inflation and rising labor costs could increase the cost of ICON&#39;s services, which it may not be able to recover from its customers. A sustained increase in these costs may require the company to hike the price of service offerings. These actions could adversely affect its future revenues, gross margin or both. In the second quarter, ICON registered an increase of 4.5% in the direct cost.</p>
<p><strong>Foreign Exchange Translation:&nbsp;</strong>Foreign exchange is a major headwind for ICON as it prepares its financial statements in U.S. dollars while some of its subsidiaries operate in other currencies like the pound sterling and the euro. In addition, the company&#39;s contracts with clients, as well as expenses, are in various local currencies, thus exposing it to fluctuations in exchange rates. These could have an adverse effect on ICLR&#39;s financial results. In the second quarter, ICON registered a net foreign exchange loss of $3.3 million.</p>
<h2>Estimate Trend</h2>
<p>The Zacks Consensus Estimate for ICON&#39;s 2024 earnings per share has remained constant at $15.09 in the past 30 days.</p>
<p>The consensus estimate for 2024 revenues is pegged at $8.51 billion. This indicates a 4.8% rise from the year-ago reported number.</p>
<h2>Key Picks</h2>
<p>Some better-ranked stocks in the broader medical space are&nbsp;<strong>TransMedix Group</strong>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>),&nbsp;<strong>Intuitive Surgical </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>) and <strong>Boston Scientific</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>).</p>
<p>TransMedix Group&#39;s earnings are expected to surge 255.8% in 2024. The company&#39;s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%. Its shares have gained 187.6% compared with the industry&#39;s 12.6% growth in the past year.</p>
<p>TMDX sports a Zacks Rank #1 (Strong Buy) at present.</p>
<p>Intuitive Surgical, sporting a Zacks Rank of 1 at present, has an estimated long-term earnings growth rate of 17.4% compared with the industry&#39;s 13.7%. Shares of the company have gained 61.4% compared with the industry&#39;s 12.5% growth over the past year.</p>
<p>ISRG&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.97%.</p>
<p>Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated earnings growth rate of 17.1% for 2024 compared with the industry&#39;s 15.7%. Shares of the company have gained 47.1% compared with the industry&#39;s 13.8% growth over the past year.</p>
<p>BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.</p>
<p><a href="https://www.zacks.com/stock/news/2326915/reasons-to-retain-icon-iclr-stock-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2326915">To read this article on Zacks.com click here.</a></p>


Offerings

Contracts

ICLR

Reasons to Retain ICON Stock in Your Portfolio Now

<p><strong>Ekso Bionics </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ekso#NASDAQ">EKSO</a>) has reached a significant milestone in terms of transforming mobility solutions, particularly for individuals with spinal cord injuries. The company recently secured initial reimbursement from the Centers for Medicare &amp; Medicaid Services for its Ekso Indego Personal exoskeleton.</p>
<p>This achievement is poised to expand Ekso Bionics&#39; foothold in the growing exoskeleton technology market, which is gaining traction in both medical and industrial sectors.</p>
<h2>Strategic Implications</h2>
<p>The CMS reimbursement marks a pivotal moment for Ekso Bionics, as it opens up substantial opportunities in a market where cost has often been a barrier to access. With tens of thousands of Medicare beneficiaries living with SCI covered by Medicare, the reimbursement approval validates the efficacy and value of the Ekso Indego Personal. It will also significantly increase the addressable market for the device, which Ekso will be working to access in late 2024 and beyond.</p>
<p>This is expected to drive demand, thereby solidifying Ekso Bionics&#39; position in the competitive landscape of medical exoskeletons.</p>
<h2>Strategic Path Forward</h2>
<p>Ekso Bionics is strategically positioned to leverage this reimbursement milestone to tap into a larger market. The company plans to collaborate with Medicare Advantage plans and commercial insurers later in 2024, aiming to make Ekso Indego Personal accessible to a broader spectrum of users.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/77/75405.jpg?v=611960233" style="height:179px; width:600px" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>Moreover, the recently launched EksoHealth Personal Program will further streamline access by ensuring that potential users are well-suited for the device, enhancing patient outcomes and satisfaction.</p>
<h2>Market Prospect</h2>
<p>Going by a Market Research Future report, the exoskeleton market is projected to grow from $1.11 billion in 2023 to $16.0 billion by 2032, exhibiting a CAGR of 39.50% during the forecast period.</p>
<p>As the exoskeleton technology market continues to expand, particularly in the medical field, Ekso Bionics&#39; achievement with CMS reimbursement is a crucial step in driving the adoption of these life-changing devices. By making advanced mobility solutions more accessible and affordable, Ekso Bionics is perfectly positioned to become a dominant player in the exoskeleton technology industry.</p>
<h2>Share Price Performance</h2>
<p>Year to date, shares of EKSO have plunged 57.2% against the industry&#39;s 9.7% growth.</p>
<h2>Zacks Rank and Other Key Picks</h2>
<p>EKSO currently carries a Zacks Rank #2 (Buy).</p>
<p>Some other top-ranked stocks in the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), <strong>TransMedics Group </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and <strong>Quest Diagnostics </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>). While Intuitive Surgical and TransMedics sport a Zacks Rank #1 (Strong Buy) each, Quest Diagnostics carries a Zacks Rank #2 (Buy).</p>
<p>Intuitive Surgical&#39;s shares have surged 61.3% in the past year. Estimates for the company&#39;s earnings have remained constant at $6.67 per share for 2024 in the past 30 days.</p>
<p>ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.</p>
<p>Estimates for TransMedics&#39; 2024 EPS have moved up 48.1% to $1.20 in the past 30 days. Shares of the company have soared 187.6% in the past year compared with the industry&#39;s 12.4% growth.</p>
<p>TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for Quest Diagnostics&#39; 2024 EPS have increased 0.2% to $8.89 in the past 30 days. In the past year, shares of DGX have risen 15.9% compared with the industry&#39;s 22.4% growth.</p>
<p>In the last reported quarter, DGX delivered an earnings surprise of 1.73%. The company has a trailing four-quarter average earnings surprise of 3.31%.</p>
<p><a href="https://www.zacks.com/stock/news/2327134/ekso-bionics-ekso-addressable-market-to-grow-on-cms-update?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2327134">To read this article on Zacks.com click here.</a></p>


EKSO

Ekso Bionics Addressable Market to Grow on CMS Update

<p><strong>SI-BONE, Inc.&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sibn#NASDAQ">SIBN</a>) has recently received FDA 510(k) clearance for its iFuse TORQ TNT implant system (&quot;TNT&quot;). The TNT implant system is the first anatomy-specific system designed to meet the biomechanical challenges presented by pelvic fragility fractures.</p>
<p>FDA has determined that TNT has the potential to provide more effective treatment of pelvic fragility fractures than the current standard of care, such as cannulated screws. The latest development highlights SI-BONE&#39;s capability to develop a platform of unique solutions that target large unmet clinical needs.</p>
<h2>About the TNT Implant System</h2>
<p>The TNT implant system is designed for the specific anatomical and bone mineral density needs of the sacrum and ilium. TNT comes with a porous threaded implant with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum and into the contralateral ilium. It includes a system specially designed for sacropelvic anatomy to reduce the rate of screw backout.</p>
<p>TNT improves early fixation and reduces the rate of screw backout, which may allow for early patient weight-bearing and mobilization. It will serve as the next-generation technology for pelvic fragility fracture fixation and sacroiliac joint fusion.</p>
<p>TNT was awarded the Breakthrough Device Designation earlier by the FDA.</p>
<h2>Industry Prospects</h2>
<p>Per a Grand View Research report, the global&nbsp;sacroiliac joint fusion market size was valued at $721.2 million in 2023&nbsp;and is anticipated to witness a CAGR of 19.8% from 2024 to 2030. Primary factors driving the market growth include the increasing prevalence of pain in the lower back, buttocks, groin and lower extremities, technological advancements and rising incidence of sacroiliitis or sacroiliac joint dysfunction.</p>
<p>Furthermore, the market growth is supported by developments in minimally invasive surgical techniques, insurance coverage improvements and major companies&#39; proactive efforts.</p>
<p>Looking at the market potential, SI-BONE&#39;s latest progress for its TNT system is well-timed.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/0d/75343.jpg?v=857288415" /></p>
<p>Image Source: Zacks Investment Research</p>
<h2>Other Recent Developments</h2>
<p>In May 2024, SI-BONE expanded its iFuse Bedrock Granite implant system portfolio with the launch of Granite 9.5, followed by FDA 510(k) premarket clearance&nbsp;in January. Granite 9.5 is suitable for patients with smaller anatomy and allows easier placement of stacked implants in the sacroalar-iliac trajectory.</p>
<h2>Price Performance of SIBN</h2>
<p>Shares of SIBN have lost 21.2% in the year-to-date period against the industry&#39;s 9.4% growth.</p>
<h2>Zacks Rank and Other Key Picks</h2>
<p>SI-BONE currently carries a Zacks Rank #2 (Buy).</p>
<p>Some other top-ranked stocks in the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), <strong>TransMedics Group </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and <strong>Quest Diagnostics </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>). While Intuitive Surgical and TransMedics sport a Zacks Rank #1 (Strong Buy) each, Quest Diagnostics currently carries a Zacks Rank of 2.</p>
<p>Intuitive Surgical&#39;s shares have surged 61.3% in the past year. Estimates for the company&#39;s earnings have remained constant at $6.67 per share for 2024 in the past 30 days.</p>
<p>ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.</p>
<p>Estimates for TransMedics&#39; 2024 earnings per share have moved up 48.1% to $1.20 in the past 30 days. Shares of the company have gained 187.6% in the past year compared with the industry&#39;s 12.4% growth.</p>
<p>TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for Quest Diagnostics&#39; 2024 EPS have increased 0.2% to $8.89 in the past 30 days. In the past year, shares of DGX have risen 15.9% compared with the industry&#39;s 22.4% growth.</p>
<p>In the last reported quarter, DGX delivered an earnings surprise of 1.73%. The company has a trailing four-quarter average earnings surprise of 3.31%.</p>
<p><a href="https://www.zacks.com/stock/news/2326907/si-bone-sibn-receives-fda-nod-for-its-tnt-implant-system?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2326907">To read this article on Zacks.com click here.</a></p>


SIBN

SI-BONE Receives FDA Nod for Its TNT Implant System

<p>It has been about a month since the last earnings report for <strong>IQVIA Holdings</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iqv#NYSE">IQV</a>). Shares have added about 3.4% in that time frame, outperforming the S&amp;P 500.</p>
<p>Will the recent positive trend continue leading up to its next earnings release, or is IQVIA due for a pullback? Before we dive into how investors and analysts have reacted as of late, let&#39;s take a quick look at the most recent earnings report in order to get a better handle on the important drivers.</p>
<h3>IQVIA Surpasses Q2 Earnings Estimates</h3>
<p><strong>IQVIA Holdings Analytics Inc. </strong>has reported impressive second-quarter 2024 results, wherein earnings and revenues surpassed the Zacks Consensus Estimate.</p>
<p>Adjusted earnings (excluding 67 cents from non-recurring items) were $2.6 per share, outpacing the Zacks Consensus Estimate by 2.3% and increasing 2.4% on a year-over-year basis. Total revenues of $3.8 billion surpassed the consensus estimate marginally and rose 2.3% from the year-ago quarter.</p>
<h3>Quarter Details</h3>
<p>Revenues from the Technology and Analytics segment were $1.5 billion, increasing 2.7% from second-quarter 2023. The metric met our estimate and increased 3.8% on a constant-currency basis.</p>
<p>The Research and Development segment&#39;s revenues were $2.2 billion, increasing 2.4% from the year-ago quarter and 3.3% on a constant-currency basis. The figure surpassed our estimate of $2.1 billion.</p>
<p>Contract Sales &amp; Medical Solutions revenues declined 2.3% on a year-over-year basis to $172 million and increased 2.8% on a constant-currency basis. It missed our estimate of $177 million.</p>
<p>Adjusted EBITDA for the second quarter of 2024 was $887 million, indicating 12.7% growth from the year-ago quarter and outpacing our expectation of $874.6 million.</p>
<p>The company exited the quarter with cash and cash equivalents of $1.5 billion compared with $1.4 billion at the end of the preceding quarter. Long-term debt (less current portion) was $12.1 billion compared with $12.8 billion at the end of the first quarter of 2024.</p>
<p>Net cash generated from operating activities was $588 million and the capital expenditure for the quarter was $143 million. The company generated a free cash flow of $445 million in the quarter.</p>
<h3>2024 Guidance</h3>
<p>For 2024, IQV updated its revenue guidance to $15.43-$15.53 billion compared with $15.33-$15.58 billion mentioned previously.</p>
<p>The company raised the adjusted EPS guidance to $11.10-$11.30 compared with $10.95-$11.25 mentioned previously. The updated guided range for adjusted EBITDA for the same period is anticipated to be $3.71-$3.77 compared with $3.70-$3.80 billion mentioned previously.</p>
<h2>How Have Estimates Been Moving Since Then?</h2>
<p>In the past month, investors have witnessed a downward trend in estimates revision.</p>
<h2>VGM Scores</h2>
<p>Currently, IQVIA has an average Growth Score of C, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.</p>
<p>Overall, the stock has an aggregate VGM Score of C. If you aren&#39;t focused on one strategy, this score is the one you should be interested in.</p>
<h2>Outlook</h2>
<p>Estimates have been broadly trending downward for the stock, and the magnitude of these revisions has been net zero. Notably, IQVIA has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.</p>
<h2>Performance of an Industry Player</h2>
<p>IQVIA belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, <strong>Intuitive Surgical, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), has gained 6.2% over the past month. More than a month has passed since the company reported results for the quarter ended June 2024.</p>
<p>Intuitive Surgical reported revenues of $2.01 billion in the last reported quarter, representing a year-over-year change of +14.5%. EPS of $1.78 for the same period compares with $1.42 a year ago.</p>
<p>For the current quarter, Intuitive Surgical is expected to post earnings of $1.65 per share, indicating a change of +13% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.</p>
<p>Intuitive Surgical has a Zacks Rank #1 (Strong Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.</p>
<p><a href="https://www.zacks.com/stock/news/2325134/iqvia-iqv-up-3-4-since-last-earnings-report-can-it-continue?cid=CS-BENZ-FT-realtime_blog-2325134">To read this article on Zacks.com click here.</a></p>


IQVIA Up 3.4% Since Last Earnings Report: Can It Continue?

<p>Citigroup  analyst Joanne Wuensch   maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Buy and raises the price target from $512 to $560.</p>


Citigroup Maintains Buy on Intuitive Surgical, Raises Price Target to $560

<p><strong>Omnicell, Inc.&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omcl#NASDAQ">OMCL</a>) recently announced Central Med Automation Service, a subscription-based solution. It is designed to help health systems establish and continuously optimize centralized medication management for Consolidated Pharmacy Services Centers (&quot;CPSCs&quot;) and similar operations.&nbsp;</p>
<h3>About Central Med Automation Service</h3>
<p>Intended to streamline medication dispensing from a central fulfillment area throughout the entire health system enterprise, this solution is expected to improve inventory visibility, scalability and patient safety.</p>
<p>The traditional methods of medication management can lead to multi-vendor environments that may complicate workflows, often creating unnecessary redundancy and increasing chances of error.Pharmacy leaders often lack the capital budgets, resources and expertise necessary to transform their infrastructure and scale it over time. Omnicell&#39;s Central Med Automation Service is designed to help health systems develop and execute a central fill strategy while providing the support necessary to ensure this environment meets the current and future medication management needs.</p>
<h3>Features of Central Med Automation Service</h3>
<p>Central Med Automation Service helps seamlessly integrate enterprise-wide robotics, smart devices and intelligent software with expert services.</p>
<p>Within the Robotics &amp; Smart Devices segment, Central Med Automation Service contains XR2 Automated Central Pharmacy System, which is aimed to improve inventory visibility, efficiency and patient safety. In the software segment, Central Med Automation Service has the Central Pharmacy Manager software, designed to support centralized medication management workflows within a CPSC, including medication ordering, receiving, picking, verifying and restocking.&nbsp;</p>
<p>Additionally, it also comes with an Inventory Optimization Service &mdash;a combination of software and expert services. This solution helps provide enterprise-wide inventory visibility and management of medication par levels, expiration dates and usage patterns delivered through data-rich dashboards.</p>
<p>The expert services include tailored guidance from Omnicell experts and dedicated on-site assistance to operate robotics and smart devices. Omnicell expert services utilize data analytics to deliver operational performance metrics, facilitating informed decision-making and continuous improvement in efficiency.</p>
<h3>More on the News</h3>
<p>Central Med Automation Service&#39;s capabilities can be extended by adding several complementary robotics, smart devices and software tools. These include Omnicell&#39;s suite of pharmacy carousels and packagers, 340B program management software and Central Pharmacy Manager Mobile Workstation.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/db/74860.jpg?v=1510659719" /></p>
<p>Image Source: Zacks Investment Research</p>
<h3>Industry Prospects</h3>
<p>Per a Grand View Research report, the global medical automation market was valued at $44.44 billion in 2022 and is expected to witness a CAGR of 9.04% from 2023 to 2030. Primary factors driving the market include the adoption of automated instruments by drug discovery departments of pharmaceutical companies, the rise in need for miniaturization, and technological advancements, coupled with the rise in demand for robot-assisted surgeries.</p>
<p>Looking at the market potential, it can be seen that the latest development is well-timed and beneficial for Omnicell&#39;s growth.</p>
<h3>Another Recent Development</h3>
<p>Earlier this year, Omnicell introduced XT Amplify &mdash; a multi-year innovation program that is intended to maximize value for hospitals, health systems and post-acute care facilities that have invested in Omnicell&#39;s XT Automated Dispensing System.</p>
<h3>Price Performance</h3>
<p>Year to date, shares of OMCL have risen 12.1% against the industry&#39;s 10.6% decline.</p>
<h3>Zacks Rank and Key Picks</h3>
<p>Omnicell currently carries a Zacks Rank #3 (Hold).</p>
<p>Some better-ranked stocks in the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), <strong>TransMedics Group </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and <strong>Quest Diagnostics </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>). While Intuitive Surgical and TransMedics sport a Zacks Rank #1 (Strong Buy) each, Quest Diagnostics carries a Zacks Rank #2 (Buy).</p>
<p>Intuitive Surgical&#39;s shares have surged 68.3% in the past year. Estimates for the company&#39;s earnings have remained constant at $6.67 per share for 2024 in the past 30 days.</p>
<p>ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.</p>
<p>Estimates for TransMedics&#39; 2024 EPS have moved up 48.1% to $1.20 cents in the past 30 days. Shares of the company have soared 153.2% in the past year compared with the industry&#39;s 12.6% growth.</p>
<p>TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for Quest Diagnostics&#39; 2024 EPS have increased 0.3% to $8.88 in the past 30 days. In the past year, shares of HAE have risen 14% compared with the industry&#39;s 21.2% growth.</p>
<p>In the last reported quarter, DGX delivered an earnings surprise of 1.73%. The company has a trailing four-quarter average earnings surprise of 3.31%.</p>
<p><a href="https://www.zacks.com/stock/news/2325052/omnicell-omcl-introduces-central-med-automation-service?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2325052">To read this article on Zacks.com click here.</a></p>


Management

OMCL

Omnicell Introduces Central Med Automation Service

American Century Focused Dynamic Growth Fund Q2 2024 Commentary

The major AI stocks have in average lower EPS growth rate than the S&P 500

The major AI stocks have on average lower EPS growth rate than the S&P 500

'No pain, no gain,' just look at stocks that jumped nearly 1,000% in a 5-year time span

Intuitive Surgical Offers Low Risk, High Return Despite Valuation Concerns

Intuitive Surgical: A Growth Machine - But Valuation? That's Another Story

Intuitive Surgical Stock Is Too Hot To Touch

Stocks that are set to benefit from either Harris or Trump winning scenarios – Barclays

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intuitive Surgical (ISRG – Research Report), HCA H...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (ISRG), HCA Healthcare (HCA) and Teleflex (TFX)

Intuitive Surgical (ISRG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Travis Steed ...

Buy Rating on Intuitive Surgical: Economic and Performance Advantages of the da Vinci 5 Robotic System

AAPL

ADBE

AIEQ

ALNY

AMZN

ANET

ARTY

ASML

AVAV

BKNG

BSQKZ

BURL

CARR

CRWD

DXCM

FARO

GOOG

GOOGL

IGPT

INTU

MSFT

MSTR

NFLX

NVDA

PEGA

PRCT

REGN

SIRI

SOUN

TSLA

Press Releases

Intuitive Announces FDA Clearance of Fifth-Generation Robotic System, da Vinci 5

Revolutionizing Medical Histories: Treatment AI's (CSE: TRUE) Pioneering Approach to Culturally Sensitive Data Collection

Sonder Capital Appoints Kate Garrett as Managing Partner to Lead Next Generation of Growth

Intuitive Announces First Quarter Earnings

Intuitive Announces Board of Directors Elections and Retirements

Intuitive Announces FDA Clearance of Revised da Vinci Xi and X Labeling on Radical Prostatectomy

Intuitive Announces Second Quarter Earnings

Intuitive President David J. Rosa Appointed to Intuitive Board of Directors

Neptune Medical Announces $97M Series D Financing and Spinout of Jupiter Endovascular

Jupiter Endovascular Exits Stealth With $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism

Comments

Intuitive Surgical

Notizie

Ultime notizie per Intuitive Surgical (NASDAQ:ISRG) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO